NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
Rhea-AI Summary
NanoViricides (AMEX:NNVC) announced on March 11, 2026 that it will present at NIBA's 152nd Investment Conference in Fort Lauderdale on March 12, 2026, and that manufacture of the Phase II clinical drug product NV-387 Oral Gummies is complete.
The company says NV-387 completed a Phase I trial with no reported adverse events and has regulatory clearance from ACOREP in the Democratic Republic of Congo to enter a Phase II trial for Monkeypox (MPox). Management will be available for investor meetings at the conference.
Positive
- Manufacture of Phase II drug product NV-387 Oral Gummies is complete
- NV-387 completed Phase I human trial with no reported adverse events
- Regulatory approval from ACOREP (DRC) to enter Phase II for Monkeypox
Negative
- Company cannot project exact IND filing dates due to external dependencies
- No financial metrics or funding details disclosed for upcoming Phase II
News Market Reaction – NNVC
On the day this news was published, NNVC gained 18.32%, reflecting a significant positive market reaction. Argus tracked a peak move of +24.5% during that session. Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $27M at that time. Trading volume was very high at 3.8x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Biotech peers show mixed moves: notable gain in SABS (10.0% up) while XCUR and GDTC are down, and scanner flags 3 peers in momentum with a median move of -3.4, suggesting broader sector volatility rather than a clearly aligned move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Orphan ODD filing | Positive | -7.9% | Filed US FDA ODD for NV-387 as MPox treatment with supporting data. |
| Feb 10 | Orphan ODD filing | Positive | +8.0% | Submitted ODD request for NV-387 in measles based on rising cases data. |
| Nov 10 | Phase II approval | Positive | -8.7% | ACOREP approved start of NV-387 Phase II MPox trial in DRC. |
| Oct 15 | Clinical strategy | Positive | +6.7% | Outlined dual-track NV-387 Phase II plans for MPox and respiratory viruses. |
| Aug 18 | Clinical findings | Positive | +2.0% | Highlighted NV-387 Phase I completion and potential to reduce cancer resurgence. |
Clinical and regulatory NV-387 updates have produced mixed reactions, with several positive-sounding milestones selling off while others traded higher, leading to an almost flat average move over recent same-tag events.
Over the past months, NanoViricides has repeatedly highlighted progress for NV-387. Key steps include ACOREP approval to start a Phase II MPox trial on Nov 10, 2025, articulation of a dual-track Phase II strategy for MPox and respiratory infections, and multiple Orphan Drug Designation applications in early 2026. These clinical‑stage developments frame today’s announcement that NV-387 Phase II oral gummies drug product manufacturing is complete and the program is moving toward dosing.
Historical Comparison
Recent clinical-trial-tagged NV-387 news produced mixed single-day moves with an average change of about 0.01, suggesting reactions have been varied despite similar development-stage updates.
Same-tag history shows NV-387 advancing from completed Phase I safety work into ACOREP-approved Phase II trials and multiple Orphan Drug Designation efforts, with today’s news adding manufacturing readiness for Phase II oral gummies.
Regulatory & Risk Context
An effective S-3 shelf registered 7,142,858 warrant-related resale shares tied to a November 10, 2025 private placement. Full cash exercise of these warrants could provide up to $13.4 million in gross proceeds, while resale shares may represent an overhang for existing holders.
Market Pulse Summary
The stock surged +18.3% in the session following this news. A strong positive reaction aligns with NanoViricides’ steady clinical progress on NV-387. Prior clinical-trial-tagged news produced mixed but modest moves, with an average change of about 0.01. The completion of Phase II oral gummies manufacturing adds tangible readiness on top of existing Phase II approvals. Investors have also faced resale overhang from an effective S-3 registering 7,142,858 shares, so warrant exercise dynamics could influence the durability of any sharp upside move.
Key Terms
phase ii clinical trial medical
phase i clinical trial medical
nanoviricide technical
AI-generated analysis. Not financial advice.
SHELTON, CT / ACCESS Newswire / March 11, 2026 / NanoViricides, Inc. (AMEX:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, is pleased to announce that it will be presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, Florida.
NanoViricides announces herewith that the manufacture of the drug product for this clinical trial, "NV-387 Oral Gummies" is now complete, in anticipation of starting dosing in patients as soon as site readiness is established.
Anil R. Diwan, PhD, President and Executive Chairman of the Company will deliver a company presentation on Thursday, March 12th at 11:50 am ET, and will be available for one-on-one investor meetings throughout the event.
NV-387, NanoViricides' lead clinical stage drug, is an extremely broad-spectrum antiviral drug that is poised to revolutionize the treatment of respiratory antiviral infections just as antibiotics have revolutionized the treatment of bacterial infections. NV-387 has multiple indications in development, including, RSV, Influenza, Coronaviruses (including COVID), Monkeypox, Smallpox, Measles, as well as Viral Acute Respiratory Infections (V-ARI), and Severe ARIs (V-SARI).
NV-387, as an oral drug, has successfully completed a Phase I clinical trial and healthy human subjects with no dropouts and no reported adverse events, indicating excellent safety and tolerability.
NV-387 has been approved to enter a Phase II clinical trial for the treatment of Monkeypox (MPox) by the regulatory agency ACOREP of the Democratic Republic of Congo (DRC).
NanoViricides is developing first-in-class antiviral drugs that act by a novel mechanism of action, enabling unparalleled broad-spectrum antiviral activity as well as safety. The Nanoviricides technology defines a novel antiviral mode of action that we call "Re-Infection Inhibition". A "nanoviricide™" is designed to look like a cell to the virus, presenting a high concentration of virus-binding ligands on its surface. Upon binding of the virus, the nanoviricide is further designed to change shape and engulf the virus particle, rendering it incapable of infecting cells.
Viruses are unlikely to escape the nanoviricide platform drugs, because the nanoviricide platform drugs mimic the essential feature on the hist cell that the viruses require, and continue to use, even as they go through a multitude of changes in their genomes and their protein makeup, via mutations, recombinations and in some cases, re-assortments.
About National Investment Banking Association (NIBA)
The National Investment Banking Association (NIBA) is a non-profit organization that has been serving the micro-cap and small-cap investment community for over 40 years. NIBA's 152nd Investment Conference website is available here:
https://nibas-152nd-investment-conference.events.accessnewswire.com/.
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. NV-387 is a unique broad-spectrum antiviral that is also effective in animal models for Monkeypox (MPox), Smallpox, as well as Measles.
Our other advanced drug candidate is NV-HHV-1 for the treatment of all Herpesvirus infections including HSV-1 "cold sores", HSV-2 "genital ulcers, VZV Shingles and Chickenpox. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants.
NV-387 has successfully completed a Phase I human clinical trial in healthy volunteers with no reported adverse events. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
Forward-looking statements: This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Media Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides
View the original press release on ACCESS Newswire
FAQ
What did NanoViricides (NNVC) announce about NV-387 on March 11, 2026?
When and where will NanoViricides (NNVC) present at NIBA's 152nd Investment Conference?
What does completion of NV-387 Phase II drug product manufacture mean for NNVC investors?
Has NV-387 received regulatory permission to start Phase II trials for Monkeypox (MPox)?
What safety data did NanoViricides (NNVC) report for NV-387 from Phase I?
